REIMAGINE Trial
The REIMAGINE Phase 3 clinical trial program evaluates CagriSema, a once-weekly combination of cagrilintide and semaglutide, in adults with type 2 diabetes across a range of treatment settings.
-
Professor Vanita R. Aroda
CagriSema monotherapy in adults with T2D not previously treated with glucose-lowering medication.
-
Dr Akshay Jain
CagriSema compared with semaglutide or cagrilintide in adults with T2D on background therapy.
-
Dr Julio Rosenstock
CagriSema added to basal insulin in adults with T2D, with or without metformin.
